SMS-oncology
SMS-oncology is a Netherlands-based, full-service contract research organization that provides clinical operations and expert advisory services for oncology drug development to small and mid-sized biotech sponsors.
- Company typePrivate
- Founded1994
- HeadquartersSchiphol, Netherlands
- Headcount51–100
- GTM typeB2B
- OfferingServices
What SMS-oncology does
SMS-oncology is a full-service contract research organization (CRO) that specializes in oncology drug development, providing both clinical operations and expert advisory services to sponsors. Founded in 2007 and headquartered in Schiphol, Netherlands, the firm operates as a privately held company with a headcount in the 51-100 range, indicating a mid-sized specialist positioning rather than a top-tier full-service platform.
The company's core offering spans clinical development, clinical pharmacology, regulatory strategy, and drug safety and pharmacovigilance services. Operational infrastructure includes an internal clinical research site network (IGNITE) and structured Centers of Expertise that group capabilities around therapeutic areas such as oncology and hematology, infectious disease and vaccines, neuroscience, immunology and inflammation, cardiometabolic disease, cell and gene therapy, and rare diseases. Scale commentary in the source dataset attributes 1,090+ clinical trials, 70+ country reach, 12 former regulators on staff, and 825+ annual regulatory submissions to the CRO platform associated with the firm.
Revenue is generated through professional-services engagements priced on a quote basis against defined study scope, marketed via a sales-led motion targeting small and mid-sized biotech sponsors. Distribution runs through direct consultation and proposal requests via the company website, supported by content marketing, podcasts, webinars, whitepapers, and event participation. Pricing is not publicly disclosed and no anchor customer logos are named in the available data.
SMS-oncology firmographics
Firmographics- Name
- SMS-oncology
- Legal name
- Allucent
- Website
- https://sms-oncology.com
- Company type
- Private
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- SMS-oncology is a Netherlands-based, full-service contract research organization that provides clinical operations and expert advisory services for oncology drug development to small and mid-sized biotech sponsors.
- Ownership category
- akta.pro rank
SMS-oncology industry classification
Industry- Product category
- Oncology Contract Research Services
- NAICS
- Other Scientific and Technical Consulting Services (54169), Management Consulting Services (54161)
- SIC
- Services-Health Services (8000), Services-Management Consulting Services (8742), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Oncology Specialty Pharmaceuticals (HLAIACAA)
- akta.pro secondary industry
- Medical Oncology (HLAKAFAB)
Keywords
Where SMS-oncology is headquartered
LocationHeadquarters
- HQ city
- Schiphol
- HQ country
- Netherlands
- HQ region
- Europe
Offices3 records
Markets served
SMS-oncology business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Clinical Research Services: Full-service contract research organization (CRO) providing clinical development, clinical pharmacology, regulatory strategy, and drug safety services to small and mid-sized biotech companies throughout all phases of drug development from early-stage to post-approval.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
SMS-oncology product offering
Product offeringCore offering
SMS-oncology is a full-service oncology CRO that delivers clinical operations together with senior-level expert advice on oncology drug development. The company runs and supports clinical trials for oncology sponsors and provides strategic consulting on development plans, regulatory pathways, and program decisions for innovative oncology therapies.
Product overview
Allucent is a global, full-service Contract Research Organization (CRO) partnering with small and mid-sized biotech and biopharma companies. The company operates as a unified service platform rather than a software product, offering integrated clinical research services across the drug development lifecycle from discovery through post-marketing approval. Core service offerings include Clinical Development Services (encompassing study start-up, IGNITE Site Network, patient recruitment, data management, biostatistics, and medical monitoring), Clinical Pharmacology Services (including PK/PD, First-in-Human studies, PopPK, and modeling/simulation), Regulatory Strategy (IND/NDA submissions, orphan drug designation, pediatric investigation plans, GxP consulting), Drug Safety & Pharmacovigilance, and Government & Public Health Services. These services are delivered through Allucent Centers of Expertise (ACEs) structured around therapeutic areas including Oncology & Hematology, Immunology & Inflammation, Neuroscience, Cell & Gene Therapy, Cardiometabolic Disease, Rare Disease, and Infectious Disease & Vaccine.
Differentiator
Problem solved
Functional benefit
Brands
- Allucent Centers of Expertise (ACEs): Designed, structured, and resourced to deliver comprehensive trial and regulatory strategy; effective patient-focused recruitment plans; and solutions meeting specific needs.
- IGNITE Site Network
- Allucent Consulting
Products and services
- Oncology Clinical Operations Full-service clinical operations for oncology trials, providing execution support for biotech and biopharma sponsors conducting oncology drug development.
- Oncology Drug Development Advisory Expert consultancy and strategic advice on oncology drug development, providing senior-level guidance on development programs and regulatory pathways to small and mid-sized biotech sponsors.
Quantifiable outcome
- 1,090+ clinical trials conducted
- +3 more outcomes
Companies that use SMS-oncology
Customer profileSegments1 record
Ideal customer profiles1 record
SMS-oncology technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
SMS-oncology partnerships and signals
Strategic signalScale indicators10 records
Recent moves5 records
Expansion highlights5 records
SMS-oncology competitors and assessment
Company assessmentDirect peers
- Medpace: Medpace is a mid-size, full-service CRO with a strong oncology franchise serving small and mid-sized biotech sponsors. Directly comparable business model and customer segment, though at significantly greater scale than SMS-oncology.
- Allucent: Allucent is a full-service CRO with strong oncology, neuroscience, and infectious disease focus serving small and mid-sized biotech sponsors. Highly comparable to SMS-oncology in target customer (small/mid-cap biotech), therapeutic emphasis on oncology, and integrated clinical + advisory offering.
- Precision for Medicine: Precision for Medicine is a CRO purpose-built around oncology and rare disease with biomarker and translational science capabilities. Comparable to SMS-oncology in oncology specialization, biotech sponsor focus, and integration of clinical operations with scientific advisory.
- Clinipace Worldwide: Clinipace is a mid-size, therapeutically-focused CRO with notable oncology and rare disease expertise serving small and mid-sized biotech. Comparable in business model, therapeutic mix, and target customer to SMS-oncology.
- Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-size CRO with therapeutic depth in oncology, neuroscience, and rare disease serving biotech and mid-cap pharma. Comparable to SMS-oncology in therapeutic specialization and biotech sponsor focus.
- Novella Clinical (IQVIA): Novella was a boutique oncology-focused CRO serving small biotech sponsors — virtually the same niche as SMS-oncology — before being acquired by IQVIA. Serves as a useful prior-art comparator for the specialist oncology CRO model.
Broad incumbents
- ICON plc: ICON is a top-tier global CRO with comprehensive oncology capabilities after multiple acquisitions. Comparable in service breadth to SMS-oncology but operates at vastly greater scale across all major therapeutic areas.
- Parexel: Parexel is a large global CRO with a sizable oncology practice. Overlaps with SMS-oncology on oncology clinical operations but operates at significantly greater scale and across many additional therapeutic areas.
- Labcorp Drug Development (Fortrea): Fortrea, spun out from Labcorp, is a large CRO with broad oncology capability and central laboratory services. Comparable to SMS-oncology on the clinical operations side, with much broader scale and ancillary lab infrastructure.
- IQVIA: IQVIA is the world's largest CRO with the most extensive oncology operational footprint. Direct overlap with SMS-oncology on oncology clinical services but at a fundamentally different scale, geographic reach, and technology stack.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights5 records
Customer concentration
SMS-oncology social profiles
Digital presenceSMS-oncology compliance and trust
Trust signalCompliance2 records
SMS-oncology financial estimates
Financial estimateRevenue estimate
Valuation estimate
SMS-oncology leadership team
Management profileNumber of profiles
SMS-oncology funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SMS-oncology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SMS-oncology
What does SMS-oncology do?
SMS-oncology is a full-service oncology CRO that delivers clinical operations together with senior-level expert advice on oncology drug development. The company runs and supports clinical trials for oncology sponsors and provides strategic consulting on development plans, regulatory pathways, and program decisions for innovative oncology therapies.
Is SMS-oncology a public or private company?
SMS-oncology is a private company. It is classified as unknown and is currently operating.
When was SMS-oncology founded?
SMS-oncology was founded in 1994. It employs 51 to 100 people.
Where is SMS-oncology based?
SMS-oncology is headquartered in Schiphol, Netherlands, in the Europe region.
How does SMS-oncology make money?
One revenue line is on record: clinical Research Services.
Who are SMS-oncology's main competitors?
Direct peers on record are Medpace, Allucent, Precision for Medicine, Clinipace Worldwide, Worldwide Clinical Trials and Novella Clinical (IQVIA). Broad incumbents are ICON plc, Parexel, Labcorp Drug Development (Fortrea) and IQVIA.
Does SMS-oncology have an API?
No public API is recorded for SMS-oncology.
What industry is SMS-oncology in?
SMS-oncology's product category is Oncology Contract Research Services. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAKAFAB, Medical Oncology. Its NAICS code is 54169 and its SIC code is 8000.